Dashboard
Manage Tickers

DTIL


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

precision-biosciences-announces-75m-underwritten-offering-of-10815m-shares-and-accompanying-warrants-to-purchase-up-to-5407500-shares-of-common-stock-at-a-combined-price-of-614
Precision BioSciences Announces ~$75M Unde...
11/10/2025 23:25:26

Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel prop...

trading-halt-halt-status-updated-at-55000-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 5:50:...
11/10/2025 22:50:05

precision-biosciences-first-in-class-gene-editing-therapy-pbgene-hbv-shows-dose-dependent-antiviral-response-and-evidence-of-viral-dna-editing-in-phase-1-eliminate-b-study-offering-potential-path-toward-chronic-hepatitis-b-cure-to-host-conference-call-tomorrow-november-11th-at-800-am-et
Precision BioSciences' First-in-Class Gene...
11/10/2025 22:25:23

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrate...

trading-halt-halted-at-45500-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:55:00 p.m. ET - ...
11/10/2025 21:55:04

precision-biosciences-q3-eps-184-misses-134-estimate-sales-13000k-miss-5400m-estimate
Precision BioSciences Q3 EPS $(1.84) Misse...
11/03/2025 12:01:52

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate ...

earnings-scheduled-for-november-3-2025
Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

precision-biosciences-to-present-new-pbgene-hbv-phase-1-data-showing-safety-and-antiviral-activity-at-aasld-liver-meeting-2025-on-nov-10-in-washington-dc
Precision BioSciences To Present New PBGEN...
10/14/2025 11:08:15

precision-biosciences-announced-the-publication-demonstrating-a-wide-variety-of-gene-edits-using-arcus-nucleases-to-stimulate-a-homology-dependent-repair-mechanism
Precision Biosciences Announced The Public...
10/09/2025 11:20:26

Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene ins...

precision-biosciences-opens-first-us-eliminate-b-site-at-massachusetts-general-hospital-actively-recruiting-chronic-hepatitis-b-patients
Precision BioSciences Opens First U.S. ELI...
10/07/2025 11:16:03

Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple gl...

iecure-to-present-otc-hope-clinical-trial-data-of-ecur-506-in-ornithine-transcarbamylase-deficiency
iECURE To Present OTC-HOPE Clinical Trial ...
10/02/2025 12:08:02

precision-biosciences-announces-late-breaking-poster-presentation-at-wms-2025-to-highlight-latest-long-term-preclinical-efficacy-and-durability-data-supporting-pbgene-dmd-for-duchenne-muscular-dystrophy-treatment
Precision BioSciences Announces Late-Break...
09/30/2025 11:06:08

- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchen...

precision-biosciences-presents-clinical-data-from-phase-1-eliminate-b-trial-of-pbgene-hbv-in-patients-with-chronic-hepatitis-b-at-ice-hbv
Precision BioSciences Presents Clinical Da...
09/12/2025 11:02:42

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...

precision-biosciences-to-be-issued-us-patent-for-pbgene-hbvarcus-nuclease-utilized-in-the-companys-lead-in-vivo-gene-editing-program-the-us-patent-will-have-an-expiration-date-in-march-2042
Precision Biosciences To Be Issued Us Pate...
09/08/2025 11:10:39

Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection i...

iecure-announces-it-will-present-additional-data-from-its-ongoing-otc-hope-clinical-trial-of-ecur-506-for-neonatal-onset-ornithine-transcarbamylase-deficiency-at-two-upcoming-conferences-in-kyoto-japan
iECURE Announces It Will Present Additiona...
08/25/2025 12:09:22

iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies...

precision-biosciences-q2-eps-213-misses-157-estimate-sales-1800k-miss-627m-estimate
Precision BioSciences Q2 EPS $(2.13) Misse...
08/07/2025 11:03:33

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

precision-biosciences-announces-phase-1-eliminate-b-cohort-1-safety-and-efficacy-at-02-mgkg-with-4769-hbsag-reduction-durable-50-response-at-7-months-sulkowski-named-head-clinical-development-advisor-and-cash-runway-extended-to-h2-2027
Precision BioSciences Announces Phase 1 EL...
08/06/2025 11:16:50

precision-biosciences-says-fda-grants-orphan-drug-designation-for-pbgene-dmd-for-treatment-of-duchenne-muscular-dystrophy
Precision BioSciences Says FDA Grants Orph...
07/23/2025 11:03:09

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...

precision-biosciences-gets-fda-orphan-drug-designation-for-pbgene-dmd-for-treatment-of-duchenne-muscular-dystrophy
Precision BioSciences Gets FDA Orphan Drug...
07/17/2025 15:52:11

https://t.co/eGDeZfYDhp

precision-biosciences-announced-dditional-preclinical-data-for-pbgene-dmd-in-vivo-gene-editing-approach-for-duchenne-muscular-dystrophy-dmd-clinical-trial-application-submission-expected-in-2025-with-clinical-data-expected-in-2026
Precision Biosciences Announced dditional ...
07/16/2025 11:05:24

New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells a...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION